FDA Approves New PARP Inhibitor for Ovarian Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers that are responding to platinum-based chemotherapy.

Read More

Stepping Into the Era of Combination Cancer Therapies, Part 2: Combining Targeted Therapies

In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015 that hold promise for combination cancer therapies, I discussed clinical trials …

Read More